Terumo "surprised" by Maquet's claims:
This article was originally published in Clinica
Terumo Cardiovascular Systems (CVS), the Ann Arbor, Michigan-based subsidiary of Japanese group Terumo, has voiced its surprise at allegations that its VirturoSaph endoscopic vessel harvesting system infringed two US patents belonging to rival Maquet Cardiovascular. Terumo CVS vice-president of sales Mark DiClemente said that the patents related to VirturoSaph were several years old and that the system has been commercially available in the US for over three years. On the other hand, Maquet has only recently entered the market through an acquisition, he added. San Jose, California-based Maquet has filed concurrent complaints against Terumo in the US International Trade Commission (ITC) and the US district court of northern California. The ITC suit seeks to prevent Terumo's product from being imported into the US, while the Californian case seeks monetary damages and an injunction.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.